SUBSCRIBE
SUBSCRIBE
News   FDA

EU Backs Nycomed’s Daxas In Deadly Lung Disease; Drug Approval Could Spur Nycomed IPO

July 6, 2010 | 
1 min read
ZURICH July 6 (Reuters) - Nycomed's [NYCMD.UL] lung drug Daxas has won European Union backing to treat patients with chronic obstructive pulmonary disease, bringing to market the first new type of treatment for the disease in over a decade.
FDA Approvals Europe
MORE ON THIS TOPIC
Background with halftone hand hold magnifier and torn papers. Collage element for search concept. Find information in internet browser.
Adcomms
Two AstraZeneca Drugs To Be Scrutinized in First FDA Cancer Advisory Panel in 9 Months
March 9, 2026
 · 
3 min read
 · 
Tristan Manalac
The white plane flies against the blue sky, leaving a white trail. Vector illustration
Rare diseases
Prasad’s Departure Could Be ‘Big Win’ for Biotech—Especially Rare Disease Space: Analysts
March 9, 2026
 · 
3 min read
 · 
Tristan Manalac
halftone magazine style banner, dislike, negative rating, hand thumbs down
Complete response letters
Incyte’s Lung Cancer Expansion Bid Thwarted by Issues at Novo’s Catalent-Acquired Site
March 9, 2026
 · 
2 min read
 · 
Tristan Manalac
FDA
FDA’s Prasad To Depart FDA Following Tumultuous Term as CBER Chief
March 6, 2026
 · 
3 min read
 · 
Heather McKenzie